# Diabetes Research Hub — Daily Iteration Report
**Date:** 2026-07-07 (Tuesday) | **Run type:** Standard (no Monday weekly sweep)

## Corpus State
- Papers: 285 total — 272 VETTED / 13 FLAGGED / **0 unvetted**
- Research paths: 56 tracked (42 VALIDATED, 12 PARTIALLY_VALIDATED, 1 CONTRADICTED, 1 EXTRACTION_ARTIFACT)
- Gaps: 15 (3 GOLD, 8 SILVER, 2 BRONZE, 1 EXPLORATORY, +1)

## Step 4 — Credibility Sweep: CLEAN
- 0 fabricated PMIDs (>42,000,000)
- 0 "zero SAE" / "zero rejection" claims
- All "achieves"/"cure" hits benign: TTP399 tissue selectivity, LADA cost-effectiveness model, microbiome-ML macro-AUC, and properly-caveated preclinical/category labels.

## Path Validation — BHB → NLRP3 inhibition (stalest overall, 73 days)
**REAFFIRMED VALIDATED** (preclinical HIGH, clinical MEDIUM — unchanged).
- **+PMID 40055596** — BMC Nephrology 2025 review; captures the previously-uncaptured 2025 source. KD/BHB delays DKD via anti-inflammation (incl. NLRP3), anti-oxidative-stress, anti-fibrosis, autophagy.
- **+PMID 40793083** — J Diabetes 2025 multi-cohort (NHANES + West China T2DM-DKD longitudinal Cox/RCS) + Mendelian randomization: **elevated circulating β-OHB independently associated with REDUCED ESRD risk** (nonlinear). First human hard-renal-outcome + MR support for the BHB→renal-protection link.
- **Offsetting caveat** (bioRxiv 2025.05.01.650510, NOT peer-reviewed, no PMID — weight cautiously): only the **acid form** of BHB (or acidic microenvironment) inhibits NLRP3; sodium-BHB does not. Implication: modest neutral-pH serum BHB rise from SGLT2i may be insufficient to engage NLRP3 → tempers the linear SGLT2i→BHB→NLRP3 story.
- **Net:** human outcome association UP, mechanistic linearity DOWN. No tier change; SGLT2i→NLRP3 remains multi-mechanism (BHB / itaconate / TXNIP). Next audit ~2026-09-01.

## Gap Audit — Gap #14 (BRONZE: LADA × Personalized Nutrition), stalest BRONZE (27 days)
**Retain BRONZE, no promotion.** Still no LADA-specific personalized-nutrition RCT with results; independent secondary source absent.
- Nearest adjacent: Berberine+Inulin LADA RCT protocol (PMC9241519, n~240, β-cell + microbiota) — nutraceutical/prebiotic, protocol-only, not a diet-personalization strategy. Added as watch item for results publication.
- Cofrogliptin-in-LADA RCT NCT07460336 (pharmacologic, starts ~May 2026) noted.

## Pipeline
`run_quality_improvements.py` — **all 41 stages [OK]**; PMIDs verified against PubMed API.

## Git
Local commit succeeded via lock-rename trick (HEAD → e3b2db8). **PUSH still BLOCKED** — no GitHub auth in sandbox. USER ACTION: `cd Diabetes_Research; git push` (optionally clean `.git/*.stale_*` cruft).
